Company / SG&A Expense
Incyte SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.4B
FY2025
5-year range
$739.6M / $1.4B
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
#19 of 213
Health Care
What the data says
Among 213 Health Care companies, Incyte is in the bottom 9% for sg&a expense. SG&A Expense has increased for 6 consecutive years, from $366M in FY2019 to $1.4B in FY2025.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of +25.9%. Top quartile in the Health Care sector.
Increased from $1.2B to $1.4B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +11.2%
- 5-Year CAGR
- +25.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 213This company $1.4B Sector average $722.3M
▼
+90.5% above sector average
Key checks
Key Insights
- Incyte's sg&a expense has grown for 6 consecutive years.
- 5-year CAGR of +25.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 10.8% year-over-year.
- Ranks #19 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.7%
- Strong return on equity: 25.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | +10.8% |
| FY2024 | $1.2B | +7.5% |
| FY2023 | $1.2B | +15.3% |
| FY2022 | $1.0B | +35.5% |
| FY2021 | $739.6M | +70.2% |
| FY2020 | $434.4M | +18.6% |
| FY2019 | $366.3M | -15.7% |
| FY2018 | $434.4M | +18.6% |
| FY2017 | $366.3M | +20.8% |
| FY2016 | $303.3M | +54.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026